E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines

被引:0
|
作者
M Lombaerts
T van Wezel
K Philippo
J W F Dierssen
R M E Zimmerman
J Oosting
R van Eijk
P H Eilers
B van de Water
C J Cornelisse
A-M Cleton-Jansen
机构
[1] Leiden University Medical Center,Department of Pathology
[2] Medical Statistics,Division of Toxicology
[3] Leiden University Medical Center,undefined
[4] Leiden/Amsterdam Center for Drug Research,undefined
[5] Leiden University,undefined
来源
British Journal of Cancer | 2006年 / 94卷
关键词
E-cadherin; epithelial–mesenchymal transition; promoter methylation; mammary cell lines; TFG; pathway;
D O I
暂无
中图分类号
学科分类号
摘要
Using genome-wide expression profiling of a panel of 27 human mammary cell lines with different mechanisms of E-cadherin inactivation, we evaluated the relationship between E-cadherin status and gene expression levels. Expression profiles of cell lines with E-cadherin (CDH1) promoter methylation were significantly different from those with CDH1 expression or, surprisingly, those with CDH1 truncating mutations. Furthermore, we found no significant differentially expressed genes between cell lines with wild-type and mutated CDH1. The expression profile complied with the fibroblastic morphology of the cell lines with promoter methylation, suggestive of epithelial–mesenchymal transition (EMT). All other lines, also the cases with CDH1 mutations, had epithelial features. Three non-tumorigenic mammary cell lines derived from normal breast epithelium also showed CDH1 promoter methylation, a fibroblastic phenotype and expression profile. We suggest that CDH1 promoter methylation, but not mutational inactivation, is part of an entire programme, resulting in EMT and increased invasiveness in breast cancer. The molecular events that are part of this programme can be inferred from the differentially expressed genes and include genes from the TGFβ pathway, transcription factors involved in CDH1 regulation (i.e. ZFHX1B, SNAI2, but not SNAI1, TWIST), annexins, AP1/2 transcription factors and members of the actin and intermediate filament cytoskeleton organisation.
引用
收藏
页码:661 / 671
页数:10
相关论文
共 50 条
  • [21] Altered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma
    Bhagat, Rahul
    Premalata, C. S.
    Shilpa, V.
    Pallavi, V. R.
    Ramesh, G.
    Vijay, C. R.
    Krishnamoorthy, Lakshmi
    TUMOR BIOLOGY, 2013, 34 (04) : 2459 - 2468
  • [22] E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells
    van Horssen, Remco
    Hollestelle, Antoinette
    Rens, Joost A. P.
    Eggermont, Alexander M. M.
    Schutte, Mieke
    ten Hagen, Timo L. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) : 365 - 377
  • [23] E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells
    Remco van Horssen
    Antoinette Hollestelle
    Joost A. P. Rens
    Alexander M. M. Eggermont
    Mieke Schutte
    Timo L. M. ten Hagen
    Breast Cancer Research and Treatment, 2012, 136 : 365 - 377
  • [24] In vivo E-cadherin expression assessed with radiolabeled E-cadherin antibodies: a potential target to image epithelial-to-mesenchymal transition in vivo.
    Dias, Gemma
    Zhang, Chengcheng
    Jenni, Silvia
    Colpo, Nadine
    Hundal, Navjit
    Lin, Kuo-Shyan
    Benard, Francois
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [25] Small molecule mediated transcriptional derepression of E-cadherin and inhibition of epithelial to mesenchymal transition
    An, Hanbing
    Deane, Natasha
    Stoops, Sydney
    Zhu, Jing
    Waterson, Alex
    Zijlstra, Andries
    Lindsley, Craig
    Beauchamp, Robert Daniel
    CANCER RESEARCH, 2015, 75
  • [26] Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition
    An, Hanbing
    Stoops, Sydney L.
    Deane, Natasha G.
    Zhu, Jing
    Zi, Jinghuan
    Weaver, Connie
    Waterson, Alex G.
    Zijlstra, Andries
    Lindsley, Craig W.
    Beauchamp, Robert Daniel
    ONCOTARGET, 2015, 6 (26) : 22934 - 22948
  • [27] Methylation of E-cadherin promoter is a frequent event in invasive breast cancer.
    Deshmane, VH
    Droufakou, S
    Hanby, AM
    Harris, WH
    Fentiman, IS
    Hart, IR
    BRITISH JOURNAL OF CANCER, 1999, 80 : 25 - 25
  • [28] Mechanisms of inactivation of E-cadherin in breast cancer cell lines
    Hiraguri, S
    Godfrey, T
    Nakamura, H
    Graff, J
    Collins, C
    Shayesteh, L
    Doggett, N
    Johnson, K
    Wheelock, M
    Herman, J
    Baylin, S
    Pinkel, D
    Gray, J
    CANCER RESEARCH, 1998, 58 (09) : 1972 - 1977
  • [29] TRANSCRIPTIONAL REGULATION OF THE HUMAN E-CADHERIN GENE IN HUMAN PROSTATE-CANCER CELL-LINES - CHARACTERIZATION OF THE HUMAN E-CADHERIN GENE PROMOTER
    BUSSEMAKERS, MJG
    GIROLDI, LA
    VANBOKHOVEN, A
    SCHALKEN, JA
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 203 (02) : 1284 - 1290
  • [30] Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter
    Banerjee, Poulomi
    Surendran, Harshini
    Chowdhury, Debabani Roy
    Prabhakar, Karthik
    Pal, Rajarshi
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2016, 94 (12): : 1397 - 1409